Zuranolone and Brexanolone for the Treatment of Postpartum Depression.
Where this comes from
- Record sourced from PubMed, PMID 41066774.
- Also identified by DOI 10.1097/AOG.0000000000006093.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This Clinical Practice Update provides revised guidance on the use of brexanolone and zuranolone in the postpartum period for depression that has onset in the third trimester or within 4 weeks postpartum. This document is a focused update of related content in Clinical Practice Guideline No. 5, Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum (Obstet Gynecol 2023;141:1262-88) and replaces the August 2023 Practice Advisory, Zuranolone for the Treatment of Postpartum Depression .
Medical subject headings
- Depression, Postpartum
- Pregnanolone
- beta-Cyclodextrins
- Antidepressive Agents